Marginal Zone Lymphomas

Hematology/Oncology Clinics of North America

Volumn 22, Issue 5, 2008, Pages 883-901

  Zucca, Emanuele ^a   Bertoni, Francesco ^a   Stathis, Anastasios ^a   Cavalli, Franco ^a  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

Extranodal lymphomas; MALT lymphoma; Marginal zone lymphoma

Indexed keywords

ALPHA INTERFERON; AMOXICILLIN; ANTHRACYCLINE; ANTIBIOTIC AGENT; BETA 2 MICROGLOBULIN; CHLORAMBUCIL; CLADRIBINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; ESOMEPRAZOLE; FLUDARABINE; LACTATE DEHYDROGENASE; LANSOPRAZOLE; METRONIDAZOLE; MITOXANTRONE; OMEPRAZOLE; PANTOPRAZOLE; PEGINTERFERON; PREDNISONE; RIBAVIRIN; RITUXIMAB; VINCRISTINE; VINCRISTINE SULFATE;

ADNEXA DISEASE; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLOOD CELL COUNT; BREAST DISEASE; BRONCHOSCOPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 18Q; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE ASSOCIATION; DNA MICROARRAY; DRUG EFFICACY; DYSPEPSIA; EPIGASTRIC PAIN; ERADICATION THERAPY; FOLLOW UP; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROSCOPY; HASHIMOTO DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPHENOTYPING; IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE; KIDNEY FUNCTION; LIVER FUNCTION; LUNG DISEASE; LUNG LAVAGE; LYMPHADENOPATHY; MALABSORPTION; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NODAL MARGINAL ZONE B CELL LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL SUPPORT; OVERALL SURVIVAL; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SEQUENCE ANALYSIS; SJOEGREN SYNDROME; SKIN DISEASE; SPLENECTOMY; SPLENIC MARGINAL ZONE B CELL LYMPHOMA; SPLENOMEGALY; STOMACH BIOPSY; STOMACH LYMPHOMA; SURVIVAL TIME; THYROID DISEASE; TREATMENT RESPONSE;

HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; WORLD HEALTH ORGANIZATION;

EID: 54049128548     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.07.011     Document Type: Review

References (115)

1. Jaffe E.S., Harris N.L., Stein H., et al. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon (France) p. 1-351
2. The Non-Hodgkin's Lymphoma Classification project: a clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89 (1997) 3909-3918
3. Isaacson P.G., Muller-Hermelink H.K., Piris M.A., et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Jaffe E.S., Harris N.L., Stein H., et al. (Eds). World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon (France) 157-160
4. Pozzi B., Cerati M., and Capella C. MALT lymphoma: pathology. In: Bertoni F., and Zucca E. (Eds). MALT lymphomas (2004), Landes Bioscience/Kluwer Academic, Georgetown (TX) 17-45
5. Zucca E., Bertoni F., Roggero E., et al. The gastric marginal zone B-cell lymphoma of MALT type. Blood 96 (2000) 410-419
6. Bertoni F., Cazzaniga G., Bosshard G., et al. Immunoglobulin heavy chain diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B cells have undergone an antigen selection process. Br J Haematol 97 (1997) 830-836
7. Wotherspoon A.C., Doglioni C., Diss T.C., et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa- associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342 (1993) 575-577
8. Roggero E., Zucca E., Pinotti G., et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 122 (1995) 767-769
9. Bayerdorffer E., Neubauer A., Rudolph B., et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 345 (1995) 1591-1594
10. Montalban C., Manzanal A., Boixeda D., et al. Helicobacter pylori eradication for the treatment of low-grade gastric MALT lymphoma: follow-up together with sequential molecular studies. Ann Oncol 8 Suppl 2 (1997) 37-39
11. Neubauer A., Thiede C., Morgner A., et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 89 (1997) 1350-1355
12. Pinotti G., Zucca E., Roggero E., et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma 26 (1997) 527-537
13. Sackmann M., Morgner A., Rudolph B., et al. Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Gastroenterology 113 (1997) 1087-1090
14. Steinbach G., Ford R., Glober G., et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 131 (1999) 88-95
15. Ruskone-Fourmestraux A., Lavergne A., Aegerter P.H., et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 48 (2001) 297-303
16. Nakamura S., Matsumoto T., Suekane H., et al. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut 48 (2001) 454-460
17. Zucca E., and Cavalli F. Are antibiotics the treatment of choice for gastric lymphoma?. Curr Hematol Rep 3 (2004) 11-16
18. Roggero E., Zucca E., Mainetti C., et al. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol 31 (2000) 263-268
19. Ferreri A.J., Guidoboni M., Ponzoni M., et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 96 (2004) 586-594
20. Lecuit M., Abachin E., Martin A., et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 350 (2004) 239-248
21. Doglioni C., Wotherspoon A.C., Moschini A., et al. High incidence of primary gastric lymphoma in northeastern Italy. Lancet 339 (1992) 834-835
22. Nakamura S., Yao T., Aoyagi K., et al. Helicobacter pylori and primary gastric lymphoma. A histopathologic and immunohistochemical analysis of 237 patients. Cancer 79 (1997) 3-11
23. Wotherspoon A.C., Ortiz-Hidalgo C., Falzon M.R., et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338 (1991) 1175-1176
24. Thieblemont C., Berger F., Dumontet C., et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 95 (2000) 802-806
25. Radaszkiewicz T., Dragosics B., and Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology 102 (1992) 1628-1638
26. Thieblemont C., and Coiffier B. MALT lymphoma: sites of presentations, clinical features and staging procedures. In: Zucca E., and Bertoni F. (Eds). MALT lymphomas (2004), Landes Bioscience/Kluwer Academic, Georgetown (TX) 60-80
27. Bertoni F., and Zucca E. Delving deeper into MALT lymphoma biology. J Clin Invest 116 (2006) 22-26
28. Farinha P., and Gascoyne R.D. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 23 (2005) 6370-6378
29. Liu H., Ye H., Dogan A., et al. T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 98 (2001) 1182-1187
30. Martinelli G., Laszlo D., Ferreri A.J., et al. Clinical activity of Rituximab in gastric marginal zone Non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 23 (2005) 1979-1983
31. Streubel B., Ye H., Du M.Q., et al. Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology 66 (2004) 476-480
32. Streubel B., Vinatzer U., Lamprecht A., et al. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 19 (2005) 652-658
33. Sagaert X., de Paepe P., Libbrecht L., et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 24 (2006) 2490-2497
34. Zucca E., Conconi A., Pedrinis E., et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 101 (2003) 2489-2495
35. Thieblemont C., Bastion Y., Berger F., et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 15 (1997) 1624-1630
36. Raderer M., Vorbeck F., Formanek M., et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer 83 (2000) 454-457
37. Cavalli F., Isaacson P.G., Gascoyne R.D., et al. MALT Lymphomas. Hematology Am Soc Hematol Educ Program (2001) 241-258
38. Du M.Q., Xu C.F., Diss T.C., et al. Intestinal dissemination of gastric mucosa-associated lymphoid tissue lymphoma. Blood 88 (1996) 4445-4451
39. Du M.Q., Peng H.Z., Dogan A., et al. Preferential dissemination of B-cell gastric mucosa-associated lymphoid tissue (MALT) lymphoma to the splenic marginal zone. Blood 90 (1997) 4071-4077
40. Drillenburg P., van der Voort R., Koopman G., et al. Preferential expression of the mucosal homing receptor integrin alpha 4 beta 7 in gastrointestinal non-Hodgkin's lymphomas. Am J Pathol 150 (1997) 919-927
41. Tsang R.W., Gospodarowicz M.K., Pintilie M., et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 21 (2003) 4157-4164
42. Musshoff K. [Clinical staging classification of non-Hodgkin's lymphomas (author's transl]. Strahlentherapie 153 (1977) 218-221 [in German]
43. de Jong D., Aleman B.M., Taal B.G., et al. Controversies and consensus in the diagnosis, work-up and treatment of gastric lymphoma: an International survey. Ann Oncol 10 (1999) 275-280
44. Ferrucci P.F., and Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?. Br J Haematol 136 (2007) 521-538
45. Thieblemont C., Dumontet C., Bouafia F., et al. Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001. Leuk Lymphoma 44 (2003) 257-262
46. Beal K.P., Yeung H.W., and Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol 16 (2005) 473-480
47. Elstrom R., Guan L., Baker G., et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101 (2003) 3875-3876
48. Hoffmann M., Kletter K., Becherer A., et al. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 64 (2003) 336-340
49. Rohatiner A., d'Amore F., Coiffier B., et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 5 (1994) 397-400
50. Liu H., Ye H., Ruskone-Fourmestraux A., et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 122 (2002) 1286-1294
51. Stolte M., Bayerdorffer E., Morgner A., et al. Helicobacter and gastric MALT lymphoma. Gut 50 Suppl 3 (2002) III19-III24
52. Ahmad A., Govil Y., and Frank B.B. Gastric mucosa-associated lymphoid tissue lymphoma. Am J Gastroenterol 98 (2003) 975-986
53. Conconi A., Cavalli F., and Zucca E. Gastric MALT lymphomas: the role of antibiotics. In: Bertoni F., and Zucca E. (Eds). MALT lymphomas (2004), Landes Bioscience/Kluwer Academic, Georgetown (TX) 81-90
54. Fischbach W., Goebeler-Kolve M.E., Dragosics B., et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 53 (2004) 34-37
55. Wundisch T., Thiede C., Morgner A., et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 23 (2005) 8018-8024
56. Chini C, Pinotti G, Stathis A, et al. Long term outcome of gastric MALT lymphoma patients treated with Anti-Helicobacter (antibiotic and proton-pump inhibitor) regimens. Blood (presented at the ASH Annual Meeting Abstracts) 110:110:Abstract 2583, 2007.
57. Zucca E., and Dreyling M. Gastric marginal zone lymphoma of MALT type: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 Suppl 2 (2008) ii70-ii71
58. Bertoni F., and Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 23 (2005) 6415-6420
59. Howden C.W., and Hunt R.H. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 93 (1998) 2330-2338
60. Bertoni F., Conconi A., Capella C., et al. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood 99 (2002) 2541-2544
61. Thiede C., Wundisch T., Alpen B., et al. Persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa- associated lymphoid tissue B-cell lymphoma. Journal of Clinical Oncology 19 (2001) 1600-1609
62. Montalban C., Santon A., Redondo C., et al. Long-term persistence of molecular disease after histological remission in low-grade gastric MALT lymphoma treated with H. pylori eradication. Lack of association with translocation t(11;18): a 10-year updated follow-up of a prospective study. Ann Oncol 16 (2005) 1539-1544
63. de Mascarel A., Ruskone-Fourmestraux A., Lavergne-Slove A., et al. Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue. Virchows Arch 446 (2005) 219-224
64. Isaacson P.G., Diss T.C., Wotherspoon A.C., et al. Long-term follow-up of gastric MALT lymphoma treated by eradication of H. pylori with antibiotics. Gastroenterology 117 (1999) 750-751
65. Fischbach W., Goebeler M.E., Ruskone-Fourmestraux A., et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut 56 (2007) 1685-1687
66. Chen L.T., Lin J.T., Tai J.J., et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst 97 (2005) 1345-1353
67. Copie-Bergman C., Gaulard P., Lavergne-Slove A., et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut 52 (2003) 1656
68. Levy M., Copie-Bergman C., Traulle C., et al. Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. Am J Gastroenterol 97 (2002) 292-297
69. Alpen B., Neubauer A., Dierlamm J., et al. Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection. Blood 95 (2000) 4014-4015
70. Ye H., Gong L., Liu H., et al. Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H. pylori eradication. Gut 55 (2006) 137-138
71. Nakamura S., Matsumoto T., Ye H., et al. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a clinicopathologic and molecular study with reference to antibiotic treatment. Cancer 107 (2006) 2770-2778
72. Cohen S.M., Petryk M., Varma M., et al. Non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue. Oncologist 11 (2006) 1100-1117
73. Schechter N.R., Portlock C.S., and Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 16 (1998) 1916-1921
74. Gospodarowicz M., and Tsang R. Radiation therapy of mucosa-associated lymphoid tissue (MALT) lymphomas. In: Bertoni F., and Zucca E. (Eds). MALT lymphomas (2004), Landes Bioscience/Kluwer Academic, Georgetown (TX) 104-129
75. Conconi A., Cavalli F., and Zucca E. MALT lymphomas: the role of chemotherapy. In: Bertoni F., and Zucca E. (Eds). MALT lymphomas (2004), Landes Bioscience/Kluwer Academic, Georgetown (TX) 99-103
76. Hammel P., Haioun C., Chaumette M.T., et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa- associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 13 (1995) 2524-2529
77. Zinzani P.L., Stefoni V., Musuraca G., et al. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 100 (2004) 2190-2194
78. Jager G., Neumeister P., Brezinschek R., et al. Treatment of extranodal marginal zone B-Cell lymphoma of mucosa- associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 20 (2002) 3872-3877
79. Jager G., Hofler G., Linkesch W., et al. Occurence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature. Haematologica 89 (2004) ECR01
80. Wohrer S., Drach J., Hejna M., et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol 14 (2003) 1758-1761
81. Thieblemont C. Clinical presentation and management of marginal zone lymphomas. Hematology Am Soc Hematol Educ Program (2005) 307-313
82. Conconi A., Martinelli G., Thieblemont C., et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 102 (2003) 2741-2745
83. Raderer M., Jager G., Brugger S., et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 65 (2003) 306-310
84. Ferreri A.J., Dolcetti R., Du M.Q., et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. Ann Oncol 19 (2008) 835-846
85. Al-Saleem T., and Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood 105 (2005) 2274-2280
86. Zucca E., Roggero E., Bertoni F., et al. Primary extranodal non-Hodgkin's lymphomas. Part 1: gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 8 (1997) 727-737
87. Matutes E., Oscier D., Montalban C., et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 22 (2008) 487-495
88. Schmid C., Kirkham N., Diss T., et al. Splenic marginal zone cell lymphoma. Am J Surg Pathol 16 (1992) 455-466
89. Isaacson P.I., Piris M.A., Catovsky D., et al. Splenic marginal zone lymphoma. In: Jaffe E.S., Harris N.L., and Stein H. (Eds). World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon (France) 135-137
90. Ruiz-Ballesteros E., Mollejo M., Rodriguez A., et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 106 (2005) 1831-1838
91. Mollejo M., Camacho F.I., Algara P., et al. Nodal and splenic marginal zone B cell lymphomas. Hematol Oncol 23 (2005) 108-118
92. Gisbert J.P., Garcia-Buey L., Pajares J.M., et al. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 125 (2003) 1723-1732
93. Chan C.H., Hadlock K.G., Foung S.K., et al. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 97 (2001) 1023-1026
94. Karavattathayyil S.J., Kalkeri G., Liu H.J., et al. Detection of hepatitis C virus RNA sequences in B-cell non-Hodgkin lymphoma. Am J Clin Pathol 113 (2000) 391-398
95. Zucca E., Roggero E., Maggi-Solca N., et al. Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin's lymphoma patients in Southern Switzerland. Haematologica 85 (2000) 147-153
96. Thalen D.J., Raemaekers J., Galama J., et al. Absence of hepatitis C virus infection in non-Hodgkin's lymphoma. Br J Haematol 96 (1997) 880-881
97. Luppi M., and Negrini R. MALT lymphoma: epidemiology and infectious agents. In: Bertoni F., and Zucca E. (Eds). MALT lymphomas (2004), Landes Bioscience/Kluwer Academic, Georgetown (TX) 1-16
98. Arcaini L., Paulli M., Boveri E., et al. Marginal zone-related neoplasms of splenic and nodal origin. Haematologica 88 (2003) 80-93
99. Arcaini L., Paulli M., Boveri E., et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 100 (2004) 107-115
100. Hermine O., Lefrere F., Bronowicki J.P., et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 347 (2002) 89-94
101. Isaacson P.G. Splenic marginal zone B cell lymphoma. In: Mason D.Y., and Harris N.L. (Eds). Human lymphoma: clinical implications of the REAL classification (1999), Springer-Verlag, London 7.1-7.6
102. Chacon J.I., Mollejo M., Munoz E., et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 100 (2002) 1648-1654
103. Thieblemont C., Felman P., Callet-Bauchu E., et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 4 (2003) 95-103
104. Berger F., Felman P., Thieblemont C., et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 95 (2000) 1950-1956
105. Troussard X., Valensi F., Duchayne E., et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC). Br J Haematol 93 (1996) 731-736
106. Catovsky D., and Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Haematol 36 (1999) 148-154
107. Mulligan S.P., Matutes E., Dearden C., et al. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol 78 (1991) 206-209
108. Lefrere F., Hermine O., Belanger C., et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 14 (2000) 573-575
109. Arcaini L., Orlandi E., Scotti M., et al. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma 4 (2004) 250-252
110. Kalpadakis C., Pangalis G.A., Dimopoulou M.N., et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 25 (2007) 127-131
111. Bennett M., Yegena S., Dave H.P., et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 26 (2008) 114
112. Nathwani B.N., Anderson J.R., Armitage J.O., et al. Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 17 (1999) 2486-2492
113. Berger F., Traverse-Glehen A., and Salles G. Nodal marginal zone B-Cell lymphoma. In: Mauch P.M., Armitage J., Coiffier B., et al. (Eds). Non-Hodgkin's lymphomas (2004), Lippincott Williams & Wilkins, Philadelphia 361-365
114. Koh L.P., Lim L.C., and Thng C.H. Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Med Oncol 17 (2000) 225-228
115. Vallisa D., Bernuzzi P., Arcaini L., et al. Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin's Lymphoma: a multicenter Italian experience. J Clin Oncol 23 (2005) 468-473